CELL INTELLIGENCE · 肿瘤细胞治疗研究

接受抗 CD38 与 BCMA 治疗的多发性骨髓瘤患者中巨细胞病毒再激活的前瞻性研究

Prospective Study of Cytomegalovirus Reactivation in Patients With Multiple Myeloma Receiving Anti-CD38 and BCMA Therapies.

在接受靶向 CD38 和 BCMA 药物的 MM 患者中，低水平 CMV 检出较为常见，但病毒血症通常具有自限性，在我们的研究队列中，尽管 CMV 检出率相对较高，却没有出现有症状的 CMV 感染。

四重暴露/难治性多发性骨髓瘤：既往接受过抗 CD38、IMiDs、蛋白酶体抑制剂与 BCMA 靶向治疗的患者

Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies.

SOHO 最新进展与后续问题 | 骨髓瘤早期复发的治疗：非 CAR-T 细胞

SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell.

Ciltacabtagene autoleucel 治疗复发/难治性多发性骨髓瘤的真实世界疗效结局：与 Cartitude-1 试验的比较研究

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.

我们的研究表明，cilta-cel 在真实世界（RW）环境下治疗的 RRMM 患者中疗效相当。

多发性骨髓瘤的演变格局：从风险分层到 T 细胞导向的先进疗法

The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies.

后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：欧洲骨髓瘤网络（EMN）共识文件

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).

SOHO 最新进展更新与后续问题 | BCMA 靶向 CAR-T 细胞：早期结果与未来方向

SOHO State-of-the-Art Updates and Next Questions | BCMA-Directed CAR T-Cells: Early Results and Future Directions.

病例报告：抗 BCMA CAR-T 细胞治疗成功治愈继发于多发性骨髓瘤的浆细胞白血病

Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy.

复发/难治性多发性骨髓瘤患者中人源化抗 BCMA 与鼠源抗 CD38 CAR-T 细胞治疗的联合

A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.

CAR 与嵌合共刺激受体联用增强 T 细胞对低抗原密度的敏感性并促进持久性

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.